{"id":"W2143695921","doi":"10.1200/jco.2007.14.4741","title":"Phase I and Pharmacokinetic Study of Daily Oral AZD2171, an Inhibitor of Vascular Endothelial Growth Factor Tyrosine Kinases, in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non–Small-Cell Lung Cancer: The National Cancer Institute of Canada Clinical Trials Group","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":120,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada); Juravinski Cancer Centre; Princess Margaret Cancer Centre; Ottawa Hospital; Queen's University; University of Ottawa","funders":"","keywords":"Medicine; Paclitaxel; Vascular endothelial growth factor; Pharmacokinetics; Carboplatin; Tyrosine-kinase inhibitor; Tyrosine kinase; Kinase; Cancer research; VEGF receptors; Internal medicine; Lung cancer; Pharmacology; Oncology; Chemotherapy; Cancer; Receptor; Cisplatin; Biochemistry; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001290458,0.001419532,0.002566813,0.0005208342,0.0005649964,0.001168977,0.001021458,0.001235226,0.001666829],"category_scores_gemma":[0.0008637284,0.0006915066,0.001069063,0.000621852,0.00115476,0.0007904529,0.0002897119,0.002974822,0.0005465997],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002067648,"about_ca_system_score_gemma":0.002458636,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002682641,"about_ca_topic_score_gemma":0.006233701,"domain_scores_codex":[0.9994019,0.0002603742,0.00002925455,0.00009788516,0.00008587926,0.0001246145],"domain_scores_gemma":[0.9993672,0.00007879262,0.0001288096,0.00005753639,0.00006017469,0.0003075693],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5918284,0.112762,0.01049796,0.001018411,0.002754557,0.000443933,0.0005879166,0.007135899,0.1215099,0.0004427969,0.008057916,0.1429603],"study_design_scores_gemma":[0.4362045,0.5209852,0.0248621,0.00003052662,0.0007393102,0.0004874196,0.00007453321,0.003015872,0.008632977,0.0001880543,0.004724826,0.00005462481],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9927949,0.002534467,0.0004593628,0.0003149549,0.00008121599,0.001758762,0.0007614414,0.00007610983,0.00121873],"genre_scores_gemma":[0.9917306,0.00206655,0.001163911,0.0003976372,0.00009431174,0.00129444,0.001747013,0.00002749907,0.001478088],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002682641,"threshold_uncertainty_score":0.01500195,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06787892216051723,"score_gpt":0.4164783429575141,"score_spread":0.3485994207969969,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}